Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 11/20 | 0.55 |
| ▸ | SCD | O00767 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21185308 | 0.83 | RAB9A (0.57) | SCD5SCDRAB9AALDH1A1MAPT | |
| SCHEMBL21185327 | 0.77 | ALDH1A1 (0.58) | SCD5SCDRAB9AALDH1A1MAPT | |
| SCHEMBL9326653 | 0.77 | PRKACA (0.59) | ALDH1A1SMN1; SMN2HPGDTSHR | |
| SCHEMBL21185328 | 0.75 | NPC1 (0.55) | SCD5SCDRAB9AALDH1A1MAPT | |
| SCHEMBL21185325 | 0.74 | RAB9A (0.55) | SCD5SCDRAB9AALDH1A1MAPT | |
| SCHEMBL21185326 | 0.74 | SCD5 (0.60) | SCD5SCDRAB9AALDH1A1MAPT | |
| SCHEMBL22566640 | 0.72 | ALDH1A1 (0.62) | SCD5SCDRAB9AALDH1A1MAPT | |
| SCHEMBL22566566 | 0.72 | ALDH1A1 (0.62) | SCD5SCDRAB9AALDH1A1MAPT | |
| SCHEMBL26428667 | 0.71 | SCD5 (0.47) | SCD5SCDRAB9AALDH1A1MAPT | |
| SCHEMBL21523608 | 0.71 | SCD5 (1.00) | SCD5SCDRAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250086-A1 | METHIONINE METABOLIC PATHWAY INHIBITORS | MIGAL - GALILEE RESEARCH INSTITUTE LTD. (IL) | 2023-08-10 | — | — | US | disclosed |
| US-20230250086-A1 | METHIONINE METABOLIC PATHWAY INHIBITORS | MIGAL - GALILEE RESEARCH INSTITUTE LTD. (IL) | 2023-08-10 | — | — | US | disclosed |
| US-11639345-B2 | Methionine metabolic pathway inhibitors | MIGAL—GALILEE RESEARCH INSTITUTE LTD. (IL) | 2023-05-02 | — | — | US | disclosed |
| US-11639345-B2 | Methionine metabolic pathway inhibitors | MIGAL—GALILEE RESEARCH INSTITUTE LTD. (IL) | 2023-05-02 | — | — | US | disclosed |
| US-20200331872-A1 | METHIONINE METABOLIC PATHWAY INHIBITORS | MIGAL - GALILEE RESEARCH INSTITUTE LTD. (IL) | 2020-10-22 | — | — | US | disclosed |
| WO-2019142192-A1 | NEW METHIONINE METABOLIC PATHWAY INHIBITORS | GAVISH-GALILEE BIO APPLICATIONS LTD. (IL) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639345-B2 | Methionine metabolic pathway inhibitors | GSS, MTR, CTH | SCD5 949/4885SCD 759/4885RAB9A 4089/4885 |
| US-20200331872-A1 | METHIONINE METABOLIC PATHWAY INHIBITORS | GSS, MTR, CTH | SCD5 949/4885SCD 759/4885RAB9A 4089/4885 |
| US-20230250086-A1 | METHIONINE METABOLIC PATHWAY INHIBITORS | GSS, MTR, CTH | SCD5 949/4885SCD 759/4885RAB9A 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.